AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 113 min read$TLRY

TLRY Stock Loses 17% in Three Months: Should You Buy, Hold or Sell?

Tilray Brands (TLRY) shares fell 17% in three months despite 11% revenue growth to $915.5M in fiscal 2026. Concerns persist about profitability and cash generation, with adjusted EBITDA at $61.1M. Competition from Canopy Growth (CGC) and Aurora Cannabis (ACB) adds pressure. Analysts remain cautious on earnings outlook.

Original reporting
theglobeandmail.com
Published Sep 11, 2026, 2:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 3:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TLRY Stock Loses 17% in Three Months: Should You Buy, Hold or Sell? — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$TLRYNeutralLow
01

Why it matters

The article offers a qualitative assessment without new quantitative data, limiting actionable insight.

02

Market read

A recap of Tilray's recent earnings; minimal new trading relevance.

03

What to watch

Potential regulatory changes in U.S. medical cannabis and upcoming Carlsberg partnership may offer upside not fully priced in.

Relevance 4/10Novelty 2/10Timing: post‑earnings commentary

Background

Tilray Brands reported FY2026 revenue growth and provided guidance for FY2027, with ongoing concerns about margins and cash generation.

Company-level read

Ticker impact

$TLRYNeutralMedium confidence
Context

Article reviews Tilray's FY2026 results and guidance, providing no new data beyond previously released earnings.

Expected impact

Sideways to slight downside as concerns over profitability persist.

Evidence & confidence

The analysis reiterates existing concerns without fresh information.

Market effects

Sector

Reinforces broader skepticism on cannabis sector profitability.

Regional

Limited impact; mainly U.S. and Canadian cannabis investors may reassess exposure.

Global

Low; no macro or cross‑sector ripple effects.

Counterpoint

What could challenge this read

Tilray's expanding international footprint could eventually drive margin improvement despite short‑term cash flow issues.

Key entities

  • company
    Tilray Brands

    Cannabis and beverage company discussed in the article.

Read at source← All news

Related articles

AUG 24
$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

aol.com3 min
AUG 23
$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

yahoo.com3 min
AUG 21
$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

fool.com3 min
AUG 7
$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

simplywall.st7 min
JUL 30
$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

yahoo.com6 min